BC Extra | Jan 27, 2020
Company News

AZ regains brazikumab rights as AbbVie paves way for closure of $63B takeout of Allergan

AstraZeneca is regaining a late-stage immunology program from Allergan in a deal designed to clear the way for U.S. and EU regulators to approve AbbVie’s $63 billion takeover of Allergan. AstraZeneca plc (LSE:AZN; NYSE:AZN) told...
BC Week In Review | May 9, 2016
Clinical News

Zenpep pancrelipase regulatory update

EMA’s CHMP recommended approval of Enzepi pancrelipase from Allergan to treat exocrine pancreatic insufficiency due to cystic fibrosis (CF) or other conditions. Allergan expects a decision from the European Commission “within a few months,” with...
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
BC Week In Review | Jan 13, 2014
Company News

Aptalis Holdings, Forest Laboratories deal

Forest will acquire gastrointestinal company Aptalis for $2.9 billion in cash. Aptalis markets nine products, including Carafate sucralfate suspension to treat active duodenal ulcers and Zenpep pancrelipase to treat exocrine pancreatic insufficiency. For the fiscal...
BioCentury | Jan 13, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell $3.58 (15%) to $20.37 on Thursday after disclosing in an SEC filing that FDA has not yet discussed with the company proposed labeling or postmarketing requirements for Feraheme...
BC Extra | Jan 9, 2014
Top Story

Forest to acquire Aptalis

Forest Laboratories Inc. (NYSE:FRX) jumped $10.54 (18%) to $69.30 on Wednesday after announcing it will acquire gastrointestinal company Aptalis Holdings Inc. (Bridgewater, N.J.) for $2.9 billion in cash. The move translates to a $2.8 billion...
BC Extra | Dec 27, 2013
Top Story

Aptalis files for $500 million IPO

Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat...
BC Extra | Oct 25, 2013
Financial News

Aptalis rumored to be planning IPO after lack of bidder

Gastrointestinal company Aptalis Pharma Inc. (Mont-Saint-Hilaire, Quebec) could not be reached for comment on rumors that the company hired Goldman Sachs and JPMorgan and is planning an IPO slated for next year. According to Reuters,...
BC Week In Review | Aug 5, 2013
Company News

Cornerstone Therapeutics, Digestive Care sales and marketing update

Cornerstone launched Pertzye pancrelipase in the U.S. to treat exocrine pancreatic insufficiency due to cystic fibrosis. A 100-dose package of Pertzye has a wholesale acquisition cost of $159 for an 8,000 USP strength and $319...
BC Week In Review | Jun 10, 2013
Company News

AbbVie sales and marketing update

AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The product comprises a combination of porcine-derived lipases, proteases and amylases. The wholesale acquisition cost of...
Items per page:
1 - 10 of 98